Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods of Japan Clinical Oncology Group study JCOG1314 (MIRACLE study).
Kataoka K, Tsushima T, Mizusawa J, Hironaka S, Tsubosa Y, Kii T, Shibuya Y, Chin K, Katayama H, Kato K, Fukuda H, Kitagawa Y; Japan Esophageal Oncology Group/Japan Clinical Oncology Group. Kataoka K, et al. Among authors: kii t. Jpn J Clin Oncol. 2015 May;45(5):494-8. doi: 10.1093/jjco/hyv012. Epub 2015 Feb 2. Jpn J Clin Oncol. 2015. PMID: 25646357 Clinical Trial.
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H, Tahara M, Mochizuki S, Kato K, Hara H, Yokota T, Kiyota N, Kii T, Chin K, Zenda S, Kojima T, Bando H, Yamazaki T, Iwasa S, Honma Y, Hamauchi S, Tsushima T, Ohtsu A. Satake H, et al. Among authors: kii t. Cancer Chemother Pharmacol. 2016 Jul;78(1):91-9. doi: 10.1007/s00280-016-3062-2. Epub 2016 May 18. Cancer Chemother Pharmacol. 2016. PMID: 27193097 Free PMC article. Clinical Trial.
Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer.
Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, Hara H, Ura T, Kojima T, Chin K, Hironaka S, Kii T, Kojima Y, Akutsu Y, Matsushita H, Kawakami K, Mori K, Nagai Y, Asami C, Kitagawa Y. Yokota T, et al. Among authors: kii t. Br J Cancer. 2016 Nov 22;115(11):1328-1334. doi: 10.1038/bjc.2016.350. Epub 2016 Nov 3. Br J Cancer. 2016. PMID: 27811857 Free PMC article. Clinical Trial.
A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.
Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, Hara H, Ura T, Kojima T, Chin K, Hironaka S, Kii T, Kojima Y, Akutsu Y, Matsushita H, Kawakami K, Mori K, Makiuchi T, Nagumo R, Kitagawa Y. Yokota T, et al. Among authors: kii t. Ann Surg Oncol. 2020 Feb;27(2):460-467. doi: 10.1245/s10434-019-07654-8. Epub 2019 Aug 2. Ann Surg Oncol. 2020. PMID: 31376034 Clinical Trial.
Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807).
Hironaka S, Tsubosa Y, Mizusawa J, Kii T, Kato K, Tsushima T, Chin K, Tomori A, Okuno T, Taniki T, Ura T, Matsushita H, Kojima T, Doki Y, Kusaba H, Fujitani K, Taira K, Seki S, Nakamura T, Kitagawa Y; Japan Esophageal Oncology Group/Japan Clinical Oncology Group. Hironaka S, et al. Among authors: kii t. Cancer Sci. 2014 Sep;105(9):1189-95. doi: 10.1111/cas.12486. Cancer Sci. 2014. PMID: 25041052 Free PMC article. Clinical Trial.
Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer.
Shitara K, Yuki S, Tahahari D, Nakamura M, Kondo C, Tsuda T, Kii T, Tsuji Y, Utsunomiya S, Ichikawa D, Hosokawa A, Ishiguro A, Sakai D, Hironaka S, Oze I, Matsuo K, Muro K. Shitara K, et al. Among authors: kii t. Br J Cancer. 2014 Jan 21;110(2):271-7. doi: 10.1038/bjc.2013.726. Epub 2013 Nov 26. Br J Cancer. 2014. PMID: 24281004 Free PMC article. Clinical Trial.
Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201.
Yamamoto S, Kawakami H, Kii T, Hara H, Kawabata R, Kawada J, Takeno A, Matsuyama J, Ueda S, Okita Y, Endo S, Kimura Y, Yanagihara K, Okuno T, Kurokawa Y, Shimokawa T, Satoh T. Yamamoto S, et al. Among authors: kii t. Eur J Cancer. 2021 Sep;154:307-315. doi: 10.1016/j.ejca.2021.06.035. Epub 2021 Jul 24. Eur J Cancer. 2021. PMID: 34311300 Clinical Trial.
A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404).
Nomura M, Kii T, Kawada J, Hirota M, Ohta T, Matsuyama J, Sakai D, Shimokawa T, Kurokawa Y, Kawakami H, Tsujinaka T, Satoh T. Nomura M, et al. Among authors: kii t. Esophagus. 2022 Oct;19(4):711-716. doi: 10.1007/s10388-022-00931-8. Epub 2022 Jun 20. Esophagus. 2022. PMID: 35723843 Clinical Trial.
52 results